Navigation Links
Orphan Drugs - Global Strategic Business Report
Date:12/4/2013

DUBLIN, December 4, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/9n9pzh/orphan_drugs) has announced the addition of the "Orphan Drugs - Global Strategic Business Report" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets.

The report profiles 113 companies including many key and niche players such as:

- AbbVie Inc.
- Actelion Pharmaceuticals Ltd.
- Amgen Inc.
- AstraZeneca plc
- Bayer HealthCare AG
- Biogen Idec Inc.
- Bristol-Myers Squibb Company
- Boehringer Ingelheim GmbH
- Celgene Corporation
- CEL-SCI Corporation
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Johnson & Johnson
- Merck & Co. Inc.
- Merck Serono International S.A.
- Novartis AG
- Pfizer Inc.
- Recordati S.p.A.
- Orphan Europe
- Sanofi SA
- Genzyme Corporation.


Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For more information visit http://www.researchandmarkets.com/research/9n9pzh/orphan_drugs

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Kinex Pharmaceuticals Announced that the U.S. Food and Drug Administration has Granted Orphan Drug Status to KX02 for the Treatment of Gliomas
2. Agility-PSR Wins "Best Contract Research Organization" in the 2013 ROAR Awards at the 4th Annual World Orphan Drug Conference in Geneva
3. CMC Contrast Granted Orphan Drug Designation by the FDA for its Liver Specific MRI Contrast Media CMC-001
4. Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases
5. FDA Designates MST-188 As An Orphan Drug For Treatment Of Acute Limb Ischemia
6. U.S. FDA Grants Orphan Drug Designation for KaloBios KB001-A in Treatment of Cystic Fibrosis Patients
7. FDA Grants Orphan Drug Designation to Omeros OMS824 for Huntingtons Disease
8. Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases
9. Bayers Investigational Drug Riociguat Granted FDA Orphan Drug Designation for Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
10. NovelMed Awarded NIH Fast Track SBIR Grant for $1.43 Million to Advance Development of its Anti-Complement Antibody for Orphan Disease
11. Orphan Drugs for Cancer: R&D and Market 2013-2023
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Worldwide ... achieve significant growth as next generation systems provide ... use radiology for cancer surgery. New systems pinpoint ... overdosing that has been such a problem previously, ... delivered. Radiosurgery robots take cancer surgery far beyond ...
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... and competitive market to drive long-term market growth ... very common set of chronic disorders that affect ... disparate in terms of their symptoms and key ... by dysregulation of immune pathways and an inappropriate ...
Breaking Medicine Technology:
(Date:2/5/2016)... New York (PRWEB) , ... February 05, 2016 , ... ... use and find themselves having to wait longer to access the treadmills. It’s a ... New Year’s resolutions to lose weight and get in shape by joining gyms, starting ...
(Date:2/5/2016)... ... , ... At its annual meeting held last week, the American Parkinson Disease ... of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We are pleased ... APDA President and CEO. “Pat has tirelessly served APDA since 2001 when he was ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Colorize ... on one drop zone to the next using Colorize's dynamic moving camera. Colorize is ... This package includes a 3D slideshow environment with 1 to 5 focus points per ...
(Date:2/5/2016)... ... 05, 2016 , ... On June 9-10, Las Vegas will ... education (CME) event presented by the Association for Comprehensive Care in Rare Diseases ... whose mission is to provide education, tools, and resources to primary care clinicians ...
(Date:2/5/2016)... Luis Obispo, CA (PRWEB) , ... February 05, 2016 , ... ... new changes that Medicare San Luis Obispo users can expect to see in 2016. ... , The two most significant changes will directly impact many San Luis Obispo seniors ...
Breaking Medicine News(10 mins):